Mwy o wybodaeth ― Cymraeg

Mae fitiligo (vitiligo) yn anhwylder croen cyffredin sy'n achosi darnau o groen gwyn oherwydd colli melanocytes. Mae ymchwil diweddar yn dangos ei fod yn clefyd hunan-immun (autoimmune disease). Er ei fod yn aml yn cael ei ystyried yn fater cosmetig, gall effeithio'n fawr ar les meddwl a bywyd bob dydd. Yn 2011, dosbarthodd arbenigwyr fath o'r enw fitiligo segmental (segmental vitiligo) ar wahân i eraill.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.

Mae gan gleifion vitiligo (fitiligo) gweithredol sawl opsiwn therapi, megis glucocorticoids systemig, phototherapy (ffototherapi), a systemic immunosuppressants (gwrthimiwnyddion systemig). Gall cleifion vitiligo (fitiligo) sefydlog gael rhyddhad rhag topical corticosteroids (corticosteroidau argroenol), topical calcineurin inhibitors (atalyddion calsinwrin argroenol), phototherapy (ffototherapi), a gweithdrefnau trawsblannu. Mae datblygiadau diweddar o ran deall prosesau sylfaenol vitiligo (fitiligo) wedi arwain at ddatblygu therapies targeted (therapïau wedi'u targedu). Ar hyn o bryd, JAK inhibitors (atalyddion JAK) yw'r rhai mwyaf addawol, gan gynnig goddefgarwch da a chanlyniadau swyddogaethol, er gwaethaf y risg o actifadu heintiau cudd a side effects (sgîl-effeithiau) systemig sy'n gyffredin ag asiantau gwrthimiwnedd eraill. Nod ymchwil parhaus yw nodi cytocinau allweddol sy'n gysylltiedig â datblygiad vitiligo (fitiligo) (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF). Mae blocio'r cytocinau hyn wedi dangos addewid mewn modelau anifeiliaid a rhai cleifion. Yn ogystal, mae ymchwiliadau i miRNA-based therapeutics a adoptive Treg cell therapy ar y gweill.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.